Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial Pipeline
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
NCT07142551
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
NCT07209189
Physician- and Patient-based Barriers to NGS Testing
NCT07209176
Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
NCT06138067
Pediatric Radiation Therapy Registry
NCT07129317
Exercise in Prostate Cancer
NCT06165302
A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
NCT06315257
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
NCT06941857
The COSMYC Trial (COmbined Suppression of MYC)
NCT06922318
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
NCT06411691
7-Days Water-Only Fasting Trial in Prostate Cancer
NCT06826924
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
NCT06564623
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
NCT06782932
Proton SBRT for Spinal Metastasis
NCT06895564
Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib
NCT06610682
Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)
NCT06803745
Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
NCT06796543
Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma
NCT06376669
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
NCT06616597
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
NCT06617923
SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization
NCT06389097
Study in Patients With Breast Cancer Leptomeningeal Metastasis
NCT06638294
Renal Retention in High Grade Upper Tract Urothelial Cancer
NCT05656235
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
NCT06398457
Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming
NCT06536881
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
NCT06001658
Behavioral Weight Loss for Cancer Survivors in Maryland: A Trial With Adaptive Interventions
NCT06463249
Exploration of Personalized Biomarkers During Neoadjuvant Radiation Therapy for Spinal and Sacral Chordoma
NCT06463262
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
NCT06205836
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
NCT05950139
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
NCT06245889
Pre-operative Hypofractionated Proton Therapy
NCT05917301
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
NCT06014255
DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
NCT06027086
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
NCT05977907
Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers
NCT04713046
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
NCT06059118
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
NCT03861676
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
NCT05658731
Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection
NCT05585684
KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC
NCT05254184
Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
NCT05083754
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
NCT05312671
Cardiometabolic Screening Program
NCT05386719
Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma
NCT05141513
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT04704505
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
NCT05013216
Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell
NCT07062549
Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca
NCT04988074
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
NCT04753879
Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer
NCT04892303
HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
NCT04131413
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
NCT04363164
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
NCT04248569
Proton Radiation Therapy Registry
NCT04376229
Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures
NCT04232085
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
NCT03786796
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
NCT03521830
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
NCT03465592
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
NCT03223922
Image-Guided Gynecologic Brachytherapy
NCT02993900
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
NCT05995821
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
NCT01804634
Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML
NCT05716009
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
NCT05823571
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
NCT05014776
Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors
NCT05121545
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
NCT04658147
Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca
NCT04848116
Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)
NCT04447651
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
NCT04209686
Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer
NCT04386746
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
NCT04117087
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
NCT03961971
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
NCT03918252
Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
NCT03875287
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
NCT03610711
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
NCT03607890
Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
NCT03573648
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
NCT03439735
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
NCT03471650
Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins
NCT02965755
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
NCT03114865
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
NCT03044613
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT02845323
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
NCT02989636
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
NCT03047135
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
NCT02923180
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
NCT02738866
Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer
NCT02743910
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
NCT02452008
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
NCT02451982
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
NCT02259621
Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme
NCT02177578
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
NCT01937117
MRI for Assessing Prostate Cancer Response
NCT01607008
Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer
NCT01088789
Johns Hopkins Breast Cancer Program Longitudinal Repository
NCT01937039
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
NCT00616967
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
NCT04301778
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 84 |
| Phase 2 | 154 |
| Phase 3 | 1 |
Therapeutic Areas
What the Pipeline for Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Shows
According to the ClinicalTrials.gov registry, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is linked to 311 US clinical trials across every stage of research activity. Of those, 202 studies are currently recruiting — about 65% of the sponsor's indexed portfolio — and 73 are already marked complete, representing roughly 23% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 238 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is Prostate Cancer with 17 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.